Company profile

GILEAD SCIENCES, INC.

NASDAQ:GILDBiotechnology: Biological Products (No Diagnostic Substances)

Drug pipeline (51)

Asset	Stage	Revenue	Trials	Status
ADEFOVIR DIPIVOXIL	approved	—	15	approved
AMBRISENTAN	approved	—	11	approved
Aztreonam	approved	—	1	approved
Bictegravir Sodium	approved	—	0	—
Bulevirtide acetate	approved	—	0	—

Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.

Clinical trials (672)

NCT ID	Phase	Status	Start	Completion	Sponsor name	Title
NCT00768300	phase3	terminated	2008-12-01	2011-02-01	Gilead Sciences	(ARTEMIS-IPF) Randomized, Placebo-Controlled Study to Evaluate Safety and Effectiveness of Ambrisentan in IPF
NCT00364026	phase2	completed	2004-06-01	—	Gilead Sciences	A Clinical Study to Evaluate the Effects of Darusentan on Safety and Efficacy in Subjects With Resistant Systolic Hypertension Receiving Combination Therapy With Three or More Blood Pressure Lowering Drugs
NCT00002453	—	completed	1999-12-01	—	Gilead Sciences	A Compassionate Use Study of Tenofovir Disoproxil Fumarate as Treatment for HIV Infection
NCT00036634	phase1_2	completed	2002-03-01	2003-02-01	Gilead Sciences	A Dose Escalation Study of Tenofovir Alafenamide in Treatment-Naive Patients
NCT00578786	phase3	completed	2004-02-01	2010-03-01	Gilead Sciences	A Long Term Study of Ambrisentan in Pulmonary Arterial Hypertension Subjects Having Completed AMB-320 (NCT00423748) or AMB-321 (NCT00423202)

FDA applications (38)

Application

Type

Applicant

Products

BLA 761115

BLA

Gilead Sciences, Inc.

BLA 761468

BLA

Gilead Sciences, Inc.

NDA 020638

NDA

GILEAD SCIENCES INC

NDA 021356

NDA

GILEAD SCIENCES INC

NDA 021449

NDA

GILEAD SCIENCES INC